

Financial Tearsheet

Company Overview

Dthera Sciences (OTCQB:DTHR), based in San Diego, Calif., is a digital therapeutics company focused on developing innovative quality of life therapies for the elderly and those suffering from cognitive decline. The Company's lead product, ReminX, is an artificial-intelligence-powered consumer health product designed to deliver reminiscence therapy digitally to individuals suffering from dementia from Alzheimer's disease and other neurodegenerative conditions, as well as for seniors experiencing social isolation. The company plans to launch ReminX commercially in the second quarter of 2018.

Recent Financial News

Date	Headline
Feb 25, 2019	Dthera Sciences Announces Exclusivity Period and Option Agreement for its Digital Therapeutic in the Japanese Market
Feb 13, 2019	Dthera Sciences SVP to Speak on Keynote Panel about Digital Therapeutics in Biopharma at OCT West Coast Conference
Feb 06, 2019	Dthera Sciences CTO to Present on Digital Therapeutics for NASA at MIT Workshop on Cognitive Performance in Space
Jan 07, 2019	Dthera Sciences Chief Technology Officer to Speak at CES Digital Health Summit
Dec 13, 2018	FDA Supports De Novo Pathway for Dthera Sciences' Breakthrough Alzheimer's Device

IR Contacts

INVESTOR RELATIONS

Marek Ciszewski, J.D.
 Managing Director, Head of Life Sciences
 LIOLIOS
 4685 MacArthur Court, Suite 400
 Newport Beach, CA 92660
 Tel: 949.574.3860
 Email: marek@liolios.com
www.liolios.com

TRANSFER AGENT

Interwest Transfer Co., Inc.
 1981 Murray Holladay Road
 Suite 100
 Salt Lake City, UT 84117
 Tel: 801-272-9294
www.interwesttc.com

AUDITORS

Sadler Gibb & Associates
 Certified Public Accountants
 2455 East Parleys Way
 Suite 320
 Salt Lake City, UT 84109
 Tel: 801-783-2950
<http://www.sadlergibb.com>

CORPORATE COUNSEL

Salt Lake City
 Kirton McConkie Building
 50 East South Temple
 Suite 400
 Salt Lake City, UT 84111
 Tel: 801-328-3600
 Fax: 801-321-4893
















Stock Performance

Today's Open	6.00
Volume	100
Day Range	6.00 - 6.00
52 Week Range	0.36 - 9.25
Bid/Ask	4.05 / 6.00
Bid/Ask Size	100 X 100
Previous Close	6.00
Market Cap	15.43 million
Shares Outstanding	2.57 million
Dividend/Yield	0.00 / 0.00%
EPS (TTM)	-1.435500
P/E Ratio (TTM)	N/A

Symbol: DTHR
 Last Trade: \$6.00
 Change (%): 0.00 (0.00%)
 Volume: 100

03/19/2019 11:50 AM ET
 Quotes delayed at least 20 mins.

Recent XBRL Filings

Filing Date ▾	Form Type	Description	View
Nov 14, 2018	10-Q	Quarterly report	  
Aug 14, 2018	10-Q	Quarterly report	  
May 15, 2018	10-Q	Quarterly report	  
Apr 02, 2018	10-K	Annual report	  
Nov 14, 2017	10-Q	Quarterly report	  

Management Team

Edward Cox, CEO

Dave Keene, CTO

Board of Directors

Michael R. Feldschuh, Director

James A. Lombard, Director

Martin S. Wolpoff, Director

Edward S. Feuer, Director

Bernhard Saxe, Director

Jonathan Feldschuh, Chief Scientific Officer